Detection of an Asymptomatic Right-Ventricle Cardiac Metastasis from a Small-Cell Lung Cancer by F-18-FDG PET/CT

Orcurto, Maria Victoria; Delaloye, Angelika Bischof; Letovanec, Igor; Favre, Martina Martins; Prior, John O.

doi:10.1097/jto.0b013e318189f60e

Cited by 36 publications

(52 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-four patients (11 men, 13 women; mean age 6 SD, 59 6 13 y) with newly diagnosed cardiac tumors routinely undergoing 18 F-FDG PET/CT (whole-body imaging with low-dose CT) as part of the initial assessment were retrospectively enrolled in this study. All patients were referred before treatment between 2004 and 2010 to screen for extracardiac tumor manifestations and to assess metabolism of the cardiac tumors.…”

Section: Patientsmentioning

confidence: 99%

“…The use of 18 F-FDG PET/CT to assess cardiac tumors is infrequently reported as single cases; the results of these reports are summarized in Table 1 (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25). To date, larger patient groups undergoing whole-body 18 F-FDG PET/CT to elucidate the diagnostic performance of PET/CT in cardiac tumors have not yet been published.…”

mentioning

confidence: 99%

“…To date, larger patient groups undergoing whole-body 18 F-FDG PET/CT to elucidate the diagnostic performance of PET/CT in cardiac tumors have not yet been published.…”

mentioning

confidence: 99%

“…Therefore, the aim of this study was to evaluate the diagnostic value of 18 F-FDG PET/CT with respect to preoperatively differentiating benign from malignant cardiac tumors.…”

mentioning

confidence: 99%

“…However, today, there is no routinely performed noninvasive imaging modality determining malignancy of cardiac tumors with sufficient accuracy. Molecular imaging methods such as 18 F-FDG with PET can visualize tumor metabolism and thereby assess metabolic activity. PET, nowadays combined with CT into PET/CT, is a clinically established method to characterize tumors (10,11).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Differentiation of Malignant and Benign Cardiac Tumors Using ¹⁸F-FDG PET/CT

Rahbar

Seifarth²,

Schäfers³

et al. 2012

J Nucl Med

233

108

View full text Add to dashboard Cite

In the diagnostic algorithm of cardiac tumors, the noninvasive determination of malignancy and metastatic spread is of major interest to stratify patients and to select and monitor therapies. In the diagnostic work-up, morphologic imaging modalities such as echocardiography or magnetic resonance tomography offer information on, for example, size, invasiveness, and vascularization. However, preoperative assessment of malignancy may be unsatisfactory. The aim of this study was to evaluate the diagnostic value of 18 F-FDG PET and the incremental diagnostic value of an optimized CT score in this clinical scenario. Methods: 18 F-FDG PET/CT scans (wholebody imaging with low-dose CT) of 24 consecutive patients with newly diagnosed cardiac tumors were analyzed (11 men, 13 women; mean age 6 SD, 59 6 13 y). The maximum standardized uptake values (SUV max ) of the tumors were measured. Patients were divided into 2 groups: benign cardiac tumors (n 5 7) and malignant cardiac tumors (n 5 17) (cardiac primaries [n 5 8] and metastases [n 5 9]). SUV max was compared between the 2 groups. Results were compared with contrast-enhanced CT, using standardized criteria of malignancy. Histology served as ground truth. Results: Mean SUV max was 2.8 6 0.6 in benign cardiac tumors and significantly higher both in malignant primary and in secondary cardiac tumors (8.0 6 2.1 and 10.8 6 4.9, P , 0.01). Malignancy was determined with a sensitivity of 100% and specificity of 86% (accuracy, 96%), after a cutoff with high sensitivity (SUV max of 3.5) was chosen to avoid false-negatives. Morphologic imaging reached a sensitivity of 82% and a specificity of 86% (accuracy, 83%). Both false-positive and false-negative decisions in morphology could be corrected in all but 1 case using a metabolic threshold with an SUV max of 3.5. In addition, extracardiac tumor manifestations were detected in 4 patients by whole-body 18 F-FDG PET/CT. Conclusion: 18 F-FDG PET/ CT can aid the noninvasive preoperative determination of malignancy and may be helpful in detecting metastases of malignant cardiac tumors.

show abstract

Section: Patientsmentioning

confidence: 99%

mentioning

confidence: 99%

“…To date, larger patient groups undergoing whole-body 18 F-FDG PET/CT to elucidate the diagnostic performance of PET/CT in cardiac tumors have not yet been published.…”

mentioning

confidence: 99%

“…Therefore, the aim of this study was to evaluate the diagnostic value of 18 F-FDG PET/CT with respect to preoperatively differentiating benign from malignant cardiac tumors.…”

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Differentiation of Malignant and Benign Cardiac Tumors Using ¹⁸F-FDG PET/CT

Rahbar

Seifarth²,

Schäfers³

et al. 2012

J Nucl Med

233

108

View full text Add to dashboard Cite

show abstract

Role of palliative radiotherapy in the management of mural cardiac metastases: who, when and how to treat? A case series of 10 patients

et al. 2016

View full text Add to dashboard Cite

Cardiac metastases (CM), although a rare manifestation of metastatic cancer, are increasing in incidence with the improved prognosis and increased longevity of many patients with cancer. This condition may be life‐threatening, especially for bulky rapidly growing tumors. Such cancer presentations may be amenable to palliative radiotherapy to improve symptoms and to prevent further cardiac function decline. Here, we report on our experience with 10 patients with mural CM who received radiotherapy (RT) to the heart with palliative intent. The radiation treatment was given in different clinical situations using different dose and fractionation, and with a variety of outcomes. Palliative RT was a reasonably effective treatment, leading to good radiographic response in five patients who were evaluable for radiologic response. The mean duration of response in responding patients was 6.3 months (range: 3–11 months). This report describing clinical dilemmas around CM radiation therapy summarizes the previous experiences with radiation in treatment of CM and may assist in the considerations of palliative treatment for these patients.

show abstract